Drug Trial Radar · NCT07117474
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Dec 24, 2024
Primary completion
Jun 9, 2026
Study completion Jun 9, 2026
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
Conditions
- Subjects With Mild Hypertension
Interventions
HRS-9563, placeboDrug
A single subcutaneous injection of HRS-9563 injection or placebo was administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of any adverse eventsTime frame: Evaluation was performed up to Day169
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.